Health resource use and costs of symptomatic knee and/or hip osteoarthritis. Issue 7 (July 2019)

• Record Type: Journal Article
• Authors: Salmon, J.H.; Rat, A.C.; Achit, H.; Ngueyon-Sime, W.; Gard, C.; Guillemin, F.; Jolly, D.; Fautrel, B.
• Is Part Of: Osteoarthritis and cartilage. Volume 27:Issue 7(2019)
• Page Start: 1011
• Page End: 1017
• Publication Date: 2019-07
• Subjects: Osteoarthritis -- Knee -- Hip -- Costs -- Health resources; Osteoarthritis -- Periodicals; Cartilage -- Periodicals; Osteoarthritis -- Periodicals; Cartilage -- Periodicals; Arthrose -- Périodiques; Articulations -- Maladies -- Périodiques; 616.7223005
• DOI: 10.1016/j.joca.2019.03.005
• Languages: English
• ISSNs: 1063-4584

Abstract

Summary: Background: Data on the economic consequences of hip and knee osteoarthritis (OA) are scarce. We aimed to estimate the annual direct and indirect costs for patients followed for hip and/or knee OA in the Knee and Hip Osteoarthritis Long term Assessment (KHOALA) cohort. Methods: The KHOALA cohort, set up from 2007 to 2009, is a French multicenter study of 878 individuals with symptomatic knee/hip OA who were 40–75 years old. Resources used were collected annually for 5 years. Costs were assigned by using official sources and expressed in 2018 euros per patient. Results: The mean annual total costs per patient over the 5-year study period were 2, 180 ± 5, 305€. The mean annual direct medical costs per patient were 2, 120 ± 5, 275€ and mean annual indirect costs per patient 180 ± 1, 735€ for people of working age. Costs increased slightly over the study period. Drugs were the largest cost share, representing over 50% of all direct costs. However, the proportion attributable to OA drugs accounted for only 10.5% of drug costs. The second cost share was hospitalizations; hip and knee prosthetic surgery accounted for 27% of surgery hospitalization costs. Health professional visits were the third cost share, accounting for 3% of direct medical costs. The median costs induced could be as high as 2 billion €/year (IQR 0.7–4.3) in France. Conclusion: Hip and knee OA costs were substantial and increased over the study period in France. However, the costs attributable to OA represented only a small fraction of overall costs.